ASH 2023 | Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Jan Bewersdorf
• 10 Dec 2023
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a retrospective analysis using the VALIDATE database, which aimed to compare the efficacy of the two currently FDA-approved hypomethylating agents (HMA), azacitidine and decitabine, in treating patients with higher-risk myelodysplastic syndromes (HR-MDS). No significant difference in overall survival (OS) was found between the two agents. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
